Status:
COMPLETED
Trained Immunity in Thyroid Carcinoma and Colon Carcinoma
Lead Sponsor:
Radboud University Medical Center
Conditions:
Thyroid Cancer, Nonmedullary
Colon Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator which is involved in the pathogenesis of both thyroid carcinoma and colon...
Eligibility Criteria
Inclusion
- At least 18 years old and mentally competent
- Newly diagnoses non-medullary thyroid carcinoma or colon carcinoma that is therapy naïve
- Planned to receive conventional treatment for the malignancy by surgery
Exclusion
- Mentally incompetent
- Pregnant or breastfeeding
- Known inflammation or infectious disease or an immunosuppressive status
- Using medication interfering with the immune system
- Reduced platelets counts or other conditions associated with an increased risk of bleeding
- Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas)
- Previous anti-cancer treatment, such as chemotherapy, radiotherapy or surgical removal or the primary tumor
- Serious psychiatric pathology
- A self-reported alcohol consumption of \>21 units per week
Key Trial Info
Start Date :
September 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT05280379
Start Date
September 19 2022
End Date
December 1 2025
Last Update
December 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RadboudUMC
Nijmegen, Gelderland, Netherlands, 6525GA